|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.92 USD | -0.92% |
|
+1.43% | -1.87% |
| 17/04 | Goldman Sachs Adjusts Incyte Price Target to $100 From $98, Maintains Neutral Rating | MT |
| 14/04 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 8.82 | 6.9 | 6.46 | 1.19 | 13.57 | |||||
Return on Total Capital | 11.52 | 9 | 8.43 | 1.66 | 19.28 | |||||
Return On Equity % | 29.73 | 8.37 | 12.5 | 0.76 | 29.87 | |||||
Return on Common Equity | 29.73 | 8.37 | 12.5 | 0.76 | 29.87 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 44.87 | 46.95 | 49 | 31.47 | 52.89 | |||||
SG&A Margin | 24.81 | 29.44 | 31.35 | 28.73 | 26.7 | |||||
EBITDA Margin % | 22.09 | 19.6 | 19.98 | 4.93 | 28 | |||||
EBITA Margin % | 20.78 | 18.14 | 18.26 | 3.29 | 26.71 | |||||
EBIT Margin % | 20.06 | 17.51 | 17.65 | 2.73 | 26.19 | |||||
Income From Continuing Operations Margin % | 31.76 | 10.04 | 16.17 | 0.77 | 25.03 | |||||
Net Income Margin % | 31.76 | 10.04 | 16.17 | 0.77 | 25.03 | |||||
Net Avail. For Common Margin % | 31.76 | 10.04 | 16.17 | 0.77 | 25.03 | |||||
Normalized Net Income Margin | 12.75 | 11.58 | 13.86 | 3.71 | 17.88 | |||||
Levered Free Cash Flow Margin | 15.03 | 22.76 | 16.53 | 15.07 | 11.86 | |||||
Unlevered Free Cash Flow Margin | 15.07 | 22.81 | 16.57 | 15.1 | 11.89 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.7 | 0.63 | 0.59 | 0.69 | 0.83 | |||||
Fixed Assets Turnover | 4.46 | 4.48 | 4.79 | 5.4 | 6.62 | |||||
Receivables Turnover (Average Receivables) | 5.44 | 5.38 | 5.32 | 5.31 | 5.48 | |||||
Inventory Turnover (Average Inventory) | 74.27 | 51.53 | 35.91 | 47.71 | 30.29 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.65 | 3.54 | 3.75 | 1.97 | 3.32 | |||||
Quick Ratio | 3.47 | 3.36 | 3.55 | 1.83 | 3.04 | |||||
Operating Cash Flow to Current Liabilities | 0.88 | 0.84 | 0.4 | 0.2 | 0.93 | |||||
Days Sales Outstanding (Average Receivables) | 67.12 | 67.8 | 68.56 | 68.89 | 66.65 | |||||
Days Outstanding Inventory (Average Inventory) | 4.91 | 7.08 | 10.16 | 7.67 | 12.05 | |||||
Average Days Payable Outstanding | 29.82 | 45.21 | 37.08 | 19.36 | 30.17 | |||||
Cash Conversion Cycle (Average Days) | 42.21 | 29.67 | 41.65 | 57.21 | 48.53 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.6 | 1.27 | 1.01 | 1.75 | 1.06 | |||||
Total Debt / Total Capital | 1.58 | 1.26 | 1 | 1.72 | 1.05 | |||||
LT Debt/Equity | 1.25 | 1.01 | 0.84 | 1.46 | 0.87 | |||||
Long-Term Debt / Total Capital | 1.23 | 1 | 0.83 | 1.43 | 0.86 | |||||
Total Liabilities / Total Assets | 23.58 | 25.18 | 23.48 | 36.67 | 25.73 | |||||
EBIT / Interest Expense | 314 | 222.95 | 255.73 | 50.85 | 554.57 | |||||
EBITDA / Interest Expense | 353.59 | 253.96 | 293.35 | 95.26 | 596.16 | |||||
(EBITDA - Capex) / Interest Expense | 258.73 | 224.76 | 280.61 | 57.43 | 571.91 | |||||
Total Debt / EBITDA | 0.09 | 0.08 | 0.07 | 0.28 | 0.04 | |||||
Net Debt / EBITDA | -3.39 | -4.7 | -4.82 | -9.66 | -2.44 | |||||
Total Debt / (EBITDA - Capex) | 0.12 | 0.09 | 0.07 | 0.46 | 0.04 | |||||
Net Debt / (EBITDA - Capex) | -4.63 | -5.31 | -5.03 | -16.02 | -2.54 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 11.98 | 13.67 | 8.87 | 14.76 | 21.22 | |||||
Gross Profit, 1 Yr. Growth % | 384.43 | 18.93 | 13.63 | -26.31 | 105.46 | |||||
EBITDA, 1 Yr. Growth % | -451.75 | 0.86 | 11 | -71.69 | 728.9 | |||||
EBITA, 1 Yr. Growth % | -382.43 | -0.76 | 9.57 | -79.32 | 1.17T | |||||
EBIT, 1 Yr. Growth % | -348.35 | -0.79 | 9.75 | -82.23 | 1.49T | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -420.79 | -64.09 | 75.42 | -94.54 | 3.84T | |||||
Net Income, 1 Yr. Growth % | -420.79 | -64.09 | 75.42 | -94.54 | 3.84T | |||||
Normalized Net Income, 1 Yr. Growth % | -377.87 | 3.22 | 30.32 | -69.26 | 567.41 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -413.97 | -64.4 | 74.34 | -94.34 | 4.17T | |||||
Accounts Receivable, 1 Yr. Growth % | 27.86 | 4.64 | 15.3 | 14.74 | 20.07 | |||||
Inventory, 1 Yr. Growth % | 69.89 | 50.5 | 49.95 | -6.51 | 71.66 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 27.78 | 1.88 | 1.49 | 2.21 | -4.51 | |||||
Total Assets, 1 Yr. Growth % | 38.54 | 18.4 | 16.11 | -19.73 | 27.8 | |||||
Tangible Book Value, 1 Yr. Growth % | 51.69 | 17.95 | 20.2 | -35.28 | 54.72 | |||||
Common Equity, 1 Yr. Growth % | 44.37 | 15.92 | 18.76 | -33.57 | 49.88 | |||||
Cash From Operations, 1 Yr. Growth % | -701.52 | 29.41 | -48.81 | -32.46 | 321.52 | |||||
Capital Expenditures, 1 Yr. Growth % | -3.4 | -57 | -58.26 | 165.54 | -31.76 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -363.2 | 72.17 | -20.94 | 4.64 | -0.97 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -364.92 | 72.08 | -20.9 | 4.6 | -0.96 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 17.61 | 12.83 | 11.25 | 11.78 | 17.95 | |||||
Gross Profit, 2 Yr. CAGR % | 22.68 | 140.03 | 16.25 | -8.49 | 22.53 | |||||
EBITDA, 2 Yr. CAGR % | 17.76 | 88.71 | 5.81 | -43.94 | 39.42 | |||||
EBITA, 2 Yr. CAGR % | 18.41 | 67.42 | 4.28 | -52.4 | 42.05 | |||||
EBIT, 2 Yr. CAGR % | 19.28 | 56.97 | 4.35 | -55.83 | 43.05 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 45.69 | 7.33 | -20.63 | -69.06 | 46.73 | |||||
Net Income, 2 Yr. CAGR % | 45.69 | 7.33 | -20.63 | -69.06 | 46.73 | |||||
Normalized Net Income, 2 Yr. CAGR % | 13.61 | 69.35 | 15.98 | -36.71 | 33.52 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 44.32 | 5.72 | -21.22 | -68.59 | 55.53 | |||||
Accounts Receivable, 2 Yr. CAGR % | 42.17 | 15.67 | 9.84 | 15.02 | 17.38 | |||||
Inventory, 2 Yr. CAGR % | 56.45 | 59.9 | 50.22 | 18.4 | 26.68 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 35.94 | 14.1 | 1.69 | 1.85 | -1.21 | |||||
Total Assets, 2 Yr. CAGR % | 19.99 | 28.07 | 17.25 | -3.46 | 1.29 | |||||
Tangible Book Value, 2 Yr. CAGR % | 24.1 | 33.76 | 19.07 | -11.8 | 0.07 | |||||
Common Equity, 2 Yr. CAGR % | 20.45 | 29.37 | 17.33 | -11.18 | -0.22 | |||||
Cash From Operations, 2 Yr. CAGR % | 2.7 | 179.01 | -18.61 | -41.2 | 68.73 | |||||
Capital Expenditures, 2 Yr. CAGR % | 52.27 | -35.55 | -57.64 | 5.28 | 34.61 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -6.53 | 112.87 | 16.67 | -9.04 | -0.1 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -6.51 | 113.95 | 16.67 | -9.04 | -0.11 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 16.64 | 16.29 | 11.49 | 12.41 | 14.84 | |||||
Gross Profit, 3 Yr. CAGR % | 31.46 | 21.42 | 87.07 | -0.14 | 19.49 | |||||
EBITDA, 3 Yr. CAGR % | 46.49 | 11.84 | 58.11 | -31.82 | 29.34 | |||||
EBITA, 3 Yr. CAGR % | 52.1 | 11.64 | 45.36 | -39.19 | 30.64 | |||||
EBIT, 3 Yr. CAGR % | 56.98 | 12.17 | 39.32 | -42.16 | 31.33 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 105.38 | -8.65 | 26.43 | -67.48 | 55.73 | |||||
Net Income, 3 Yr. CAGR % | 105.38 | -8.65 | 26.43 | -67.48 | 55.73 | |||||
Normalized Net Income, 3 Yr. CAGR % | 48.62 | 10.04 | 55.19 | -25.5 | 32.75 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 103.06 | -9.49 | 24.9 | -67.25 | 61.56 | |||||
Accounts Receivable, 3 Yr. CAGR % | 26.16 | 28.36 | 15.55 | 11.45 | 16.68 | |||||
Inventory, 3 Yr. CAGR % | 58.81 | 54.44 | 56.51 | 28.26 | 34.01 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 32.95 | 23.48 | 9.73 | 1.86 | -0.31 | |||||
Total Assets, 3 Yr. CAGR % | 23.08 | 19.45 | 23.96 | 3.34 | 6.01 | |||||
Tangible Book Value, 3 Yr. CAGR % | 30.6 | 22.01 | 29.08 | -2.83 | 6.37 | |||||
Common Equity, 3 Yr. CAGR % | 25.09 | 18.92 | 25.73 | -2.94 | 5.75 | |||||
Cash From Operations, 3 Yr. CAGR % | 30.63 | 10.92 | 58.54 | -23.52 | 13.37 | |||||
Capital Expenditures, 3 Yr. CAGR % | 35.05 | -0.1 | -44.24 | -21.89 | -8.89 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 28.99 | 14.58 | 53.01 | 12.52 | -7.59 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 28.91 | 14.58 | 53.56 | 12.5 | -7.58 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 21.98 | 17.18 | 14.45 | 14.46 | 14.03 | |||||
Gross Profit, 5 Yr. CAGR % | 23.54 | 62.05 | 25.15 | 8.43 | 57.94 | |||||
EBITDA, 5 Yr. CAGR % | 28.16 | 31.09 | 28.62 | -15.16 | 50.44 | |||||
EBITA, 5 Yr. CAGR % | 28.58 | 24.91 | 30.79 | -20.62 | 44.27 | |||||
EBIT, 5 Yr. CAGR % | 29.58 | 21.55 | 33.32 | -22.74 | 41.04 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 55.53 | 1.7 | 40.41 | -40.76 | 34.19 | |||||
Net Income, 5 Yr. CAGR % | 55.53 | 1.7 | 40.41 | -40.76 | 34.19 | |||||
Normalized Net Income, 5 Yr. CAGR % | 36.23 | 24.12 | 34.58 | -11.8 | 46.33 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 51.22 | -0.14 | 39.04 | -40.73 | 36.35 | |||||
Accounts Receivable, 5 Yr. CAGR % | 32.99 | 19.49 | 19.36 | 22.85 | 16.28 | |||||
Inventory, 5 Yr. CAGR % | 46.71 | 45.31 | 55.32 | 38.87 | 43.82 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 34.99 | 24.13 | 19.43 | 14.33 | 5.22 | |||||
Total Assets, 5 Yr. CAGR % | 24.66 | 20.46 | 20.72 | 9.7 | 14.34 | |||||
Tangible Book Value, 5 Yr. CAGR % | 250.34 | 26.97 | 25.86 | 7.16 | 16.58 | |||||
Common Equity, 5 Yr. CAGR % | 55.14 | 21.79 | 21.93 | 5.82 | 14.63 | |||||
Cash From Operations, 5 Yr. CAGR % | 19.72 | 59.83 | 8.11 | -13.95 | 62.54 | |||||
Capital Expenditures, 5 Yr. CAGR % | 8.52 | -6.86 | -15.06 | 2.02 | -20.67 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 21.5 | 44.66 | 23.91 | 4.47 | 29.02 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 22.65 | 45.77 | 23.86 | 4.47 | 29.29 |
- Stock Market
- Equities
- INCY Stock
- Financials Incyte Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















